bluebird bio (BLUE) Provides Updated Findings from Reported Case of AML in LentiGlobin for Sickle Cell Disease Gene Therapy Program

Go back to bluebird bio (BLUE) Provides Updated Findings from Reported Case of AML in LentiGlobin for Sickle Cell Disease Gene Therapy Program

bluebird bio Provides Updated Findings from Reported Case of Acute Myeloid Leukemia (AML) in LentiGlobin for Sickle Cell Disease (SCD) Gene Therapy Program

March 10, 2021 7:00 AM EST

Analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in clinical study of LentiGlobin for SCD

bluebird bio has initiated process with regulators to resume clinical studies

Company to hold conference call and webcast today, March 10, 2021, 8:00 AM EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More